Human embryo gene editing shows accuracy but carries clinical risks

Researchers at Columbia University Vagelos College of Physicians and Surgeons have demonstrated that advanced base editing techniques can accurately modify DNA in single-cell human embryos. While the study, published in Nature, showed that some edits were 100% successful and allowed for normal development over 6-7 days, it also revealed unpredictable changes that make the technology currently unsafe for clinical use.

The research aims to help scientists understand early human development and how embryos manage DNA damage. Long-term goals include improving the safety and efficiency of IVF treatments to prevent genetic abnormalities.

However, the rise of CRISPR-based technologies has intensified debates regarding germline editing. Unlike somatic cell therapies, which affect only the individual patient, germline modifications made to embryos are heritable and passed to future generations. This distinction has raised significant ethical and legal questions globally, including discussions on whether constitutional frameworks can protect embryos from non-consensual genetic modification.